Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.
On the company’s first-quarter 2026 earnings call, Chief Executive Officer Dennis Lanfear said Coherus is pursuing a strategy centered on LOQTORZI, its PD-1 inhibitor, both as a commercial product in nasopharyngeal cancer and as a potential combination therapy with pipeline assets in other cancers.
